For hematopoietic toxicity, as shown in Figure 3, compared with standalone endocrine therapy, the combination therapy of three CDK4/6 inhibitors with AI or Fulvestrant is more likely to result in neutropenia, thrombocytopenia and anemia. Here, CDK4 is linked to anemia (phenotype).